Gyro Tablet 10 mg (Empagliflozin)
Empagliflozin 10mg
Tablet · Prescription medication
IYUN Pharmaceutical Co., Ltd.
MFDS item code 202102286 · Approved 2021.03.12
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used to help control blood sugar in adults with type 2 diabetes, in addition to diet and exercise. It can be administered alone, or if blood sugar control is insufficient, it may be used in combination with other diabetes medications such as metformin, pioglitazone, sulfonylureas, insulin, or linagliptin. Special caution is required by professionals when using this medication in type 2 diabetes patients with existing cardiovascular disease. It assists in diabetes management through effective blood sugar control.
The recommended dose of this medicine is 10 mg once daily, whether used as monotherapy or as add-on combination therapy with other antihyperglycemic agents, such as insulin. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3, Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment No dosage adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistently reduced glomerular filtration rate of < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. Discontinue this medicine if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. • Patients with hepatic impairment No dosage adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dosage adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of this medicine is not recommended in patients aged 85 years or older because clinical experience is limited (see Precautions for Use, section 4, General Precautions).
This medication should not be used in patients with an allergy to the active ingredient or any other components. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. It should not be used in patients with severely impaired kidney function, defined as a glomerular filtration rate of less than 30 mL/min/1.73m² or those with end-stage renal disease or on dialysis. This medication contains lactose, therefore it should not be administered to patients with lactose intolerance, galactose intolerance, or hereditary lactase deficiency. In patients with slightly impaired kidney function, careful monitoring is required, with potential need for dose adjustment or discontinuation during treatment. The use of this medication is not recommended in patients with severe heart failure, and caution should also be exercised in mild cases. When used in conjunction with insulin or insulin secretagogues, the risk of hypoglycemia may increase, necessitating potential dose reduction of these medications. While using this medication, individuals should be cautious of possible side effects such as hypoglycemia, genital infections, urinary tract infections, increased urination, and decreased fluid volume. Particularly, serious metabolic acidosis known as ketoacidosis may occur, and immediate treatment should be sought if symptoms appear; this medication should be discontinued. Elderly patients or those at risk of fluid volume depletion should be closely monitored for symptoms of dehydration and low blood pressure. This medication may increase the risk of serious infections such as urosepsis, pyelonephritis, and necrotizing fasciitis, necessitating prompt treatment for any signs of infection. Use during pregnancy is not recommended, and it should be discontinued if pregnancy is confirmed. Use during breastfeeding is also not recommended, thus breastfeeding should be stopped. The safety and efficacy of this medication in children under 18 have not been established. In case of overdose, appropriate treatment should be sought; there is no information on whether this medication can be removed by hemodialysis. Store this medication in a tightly sealed container away from children's reach and do not transfer to other containers. When driving or operating machinery, caution should be exercised considering the risk of hypoglycemia. Regular monitoring of kidney function, fluid status, and signs of infection during medication use is essential.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air and moisture. The storage temperature should be maintained between 1 to 30 degrees Celsius.
Light yellow, biconvex, round film-coated tablet
10 tablets/box [(10 tablets/PTP × 1)], 30 tablets/box [(10 tablets/PTP × 3)], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 10mg
Tablet · Prescription medication
IYUN Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.